Eva C Coopmans
Overview
Explore the profile of Eva C Coopmans including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huynh K, Al-Gully J, Montero-Cabezas J, Scheffers L, Verstegen M, Biermasz N, et al.
Eur J Endocrinol
. 2025 Jan;
192(2):S1-S14.
PMID: 39880368
Objective: Cardiovascular disease in acromegaly patients remains a major cause of morbidity and all-cause mortality. This systematic review investigates the effect of the first growth hormone-lowering intervention on cardiac parameters....
2.
Huynh K, Coopmans E, Zamanipoor Najafabadi A, Dirven L, Peerdeman S, Biermasz N, et al.
J Neurooncol
. 2023 Feb;
161(2):371.
PMID: 36780104
No abstract available.
3.
Huynh K, Coopmans E, Zamanipoor Najafabadi A, Dirven L, Peerdeman S, Biermasz N, et al.
J Neurooncol
. 2023 Jan;
161(2):357-370.
PMID: 36626042
Purpose: Few studies have reported on healthcare utilization and costs for intracranial meningioma patients, while the tumor and its treatment profoundly affect patients' functioning and well-being. Here we evaluated healthcare...
4.
Coopmans E, Andela C, Claessen K, Biermasz N
Endocrinol Metab Clin North Am
. 2022 Oct;
51(4):709-725.
PMID: 36244688
Acromegaly has a substantial negative impact on quality of life (QoL). This review aims to discuss the impact of acromegaly on QoL from the clinical perspective as well as from...
5.
Coopmans E, Korbonits M
Clin Endocrinol (Oxf)
. 2022 Mar;
97(4):424-435.
PMID: 35349723
Objective: Most pituitary tumours occur sporadically without a genetically identifiable germline abnormality, a small but increasing proportion present with a genetic defect that predisposes to pituitary tumour development, either isolated...
6.
Coopmans E, van der Lely A, Neggers S
J Clin Endocrinol Metab
. 2022 Jan;
107(6):1759-1766.
PMID: 35090028
Although most tumors in patients with acromegaly are benign and are cured or controlled by surgery and/or first-generation somatostatin receptor ligands therapy, some can behave more aggressively and are resistant...
7.
Coopmans E, Postma M, Wolters T, van Meyel S, Netea-Maier R, van Beek A, et al.
J Clin Endocrinol Metab
. 2021 Feb;
106(6):1783-1792.
PMID: 33544833
Context: Transsphenoidal surgery (TSS) is the primary treatment of choice in acromegaly. It is important to identify patients in whom surgical cure is not attainable at an early stage, both...
8.
Coopmans E, Korevaar T, van Meyel S, Daly A, Chanson P, Brue T, et al.
J Clin Endocrinol Metab
. 2020 Jun;
105(9).
PMID: 32589751
Context: First-generation somatostatin receptor ligands (fg-SRLs) represent the mainstay of medical therapy for acromegaly, but they provide biochemical control of disease in only a subset of patients. Various pretreatment biomarkers...
9.
Coopmans E, Berk K, El-Sayed N, Neggers S, van der Lely A
N Engl J Med
. 2020 May;
382(22):2161-2162.
PMID: 32459928
No abstract available.
10.
Coopmans E, Schneiders J, El-Sayed N, Erler N, Hofland L, van der Lely A, et al.
Eur J Endocrinol
. 2020 May;
182(6):595-605.
PMID: 32375119
Objective: T2-signal intensity and somatostatin (SST) receptor expression are recognized predictors of therapy response in acromegaly. We investigated the relationship between these predictors and the hormonal and tumoral responses to...